(Q44375021)

English

Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma

scientific article published in April 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Francisco J Esteva

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Gabriel N Hortobagyi

10

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

9

object named as

Aman U Buzdar

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

Fan Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Ying Yang

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Terry Smith

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Shu-Wan Kau

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Judy M McConathy

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Henry M Kuerer

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

W Fraser Symmans

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Lajos Pusztai

11

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

0 references

publication date

1 April 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

97

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1758-1765

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

21 January 2018

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Obtaining Confidence Intervals for the Risk Ratio in Cohort Studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11245

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11245

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44375021&oldid=2121329390"